Trial Profile

A Clinical Trial to Evaluate MVR-T3011 Intravenous Delivery

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T 3011 (Primary)
Indications Appendiceal cancer; Cancer; Endometrial cancer; Gallbladder cancer; Tumours
Focus Adverse reactions
Sponsors Immvira Pharma

Most Recent Events

09 Nov 2023 Results published in the Media Release
09 Nov 2023 Status changed from planning to completed.
19 Apr 2021 According to an Immvira media release, the company has submitted an IND application for MVR-T3011 intravenous administration to the U.S. FDA in January 2021 and expects to recruit patients in five leading U.S. research cancer centers within the next few weeks.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com